Division of Metabolism, Endocrinology and Nutrition, University of Washington, 1959 NE Pacific Street, UW Mailbox 356426, Seattle, WA, 98195-6426, USA.
Drugs. 2019 Jan;79(1):11-20. doi: 10.1007/s40265-018-1038-8.
Unplanned pregnancies are an ongoing global burden, posing health and economic risks for women, children, and families. Advances in male contraception have been historically stymied by concerning failure rates, problematic side effects, and perceived market limitations. However, increased interest in reliable and reversible options for male contraception have resulted in resurgent efforts to introduce novel contraceptives for men. Hormonal male contraception relies on exogenous androgens and progestogens that suppress gonadotropin production, thereby suppressing testicular testosterone and sperm production. In many men, effective suppression of spermatogenesis can be achieved by androgen-progestin combination therapy. Small-scale contraceptive efficacy studies in couples have demonstrated effectiveness and reversibility with male hormonal methods, but side effects related to mood, sexual desire and cholesterol remain concerning. A number of novel androgens have reached clinical testing as potential contraceptive agents; many of these have both androgenic and progestogenic action in a single, modified steroid, thereby holding promise as single-agent contraceptives. Currently, these novel steroids hold promise as both a "male pill" and long-acting injections. Among non-hormonal methods, studies of reversible vaso-occlusive methods (polymers that block transport of sperm through the vas deferens) are ongoing, but reliable reversibility and long-term safety in men have not been established. Proteins involved in sperm maturation and motility are attractive targets, but to date both specificity and biologic redundancy have been challenges for drug development. In this review, we aim to summarize landmark studies on male contraception, highlight the most recent advances and future development in this important field of public health and medicine.
意外怀孕是一个全球性的问题,会给妇女、儿童和家庭带来健康和经济风险。男性避孕的进展在历史上一直受到令人担忧的失败率、有问题的副作用和被认为的市场限制的阻碍。然而,对可靠和可逆的男性避孕选择的兴趣增加,促使人们重新努力为男性引入新的避孕方法。激素男性避孕依赖于外源性雄激素和孕激素,它们抑制促性腺激素的产生,从而抑制睾丸睾酮和精子的产生。在许多男性中,雄激素-孕激素联合疗法可以有效地抑制精子发生。在夫妇中的小规模避孕效果研究表明,男性激素方法具有有效性和可逆性,但与情绪、性欲和胆固醇相关的副作用仍然令人担忧。许多新型雄激素已进入临床测试,作为潜在的避孕剂;其中许多在单个修饰类固醇中具有雄激素和孕激素作用,因此有望成为单一药物避孕剂。目前,这些新型类固醇有望成为“男性避孕药”和长效注射剂。在非激素方法中,可逆血管阻塞方法(阻止精子通过输精管运输的聚合物)的研究正在进行中,但在男性中可靠的可逆性和长期安全性尚未得到证实。参与精子成熟和运动的蛋白质是有吸引力的靶点,但迄今为止,药物开发的特异性和生物学冗余性一直是挑战。在这篇综述中,我们旨在总结男性避孕的标志性研究,强调这一重要公共卫生和医学领域的最新进展和未来发展。